4 results on '"Boers, Maarten"'
Search Results
2. A simple model that suggests possible cost savings when modified-release prednisone 5 mg/day is added to current treatment in patients with active rheumatoid arthritis.
- Author
-
Boers, Maarten and Buttgereit, Frank
- Subjects
- *
ACADEMIC medical centers , *BIOLOGICAL products , *COMBINATION drug therapy , *CONTROLLED release preparations , *COST effectiveness , *GLUCOCORTICOIDS , *MEDICAL cooperation , *PREDNISONE , *RESEARCH , *RESEARCH funding , *RHEUMATOID arthritis , *RANDOMIZED controlled trials - Abstract
Objective. The effects of a 12-week treatment with modified-release prednisone (MR-pred) on the costs of drug treatment of RA were modelled.Methods. With the results of a recent randomized trial as source data, we expressed the effect of treatment (MR-pred vs placebo) on the decrease in the proportion of RA patients meeting disease activity thresholds for reimbursement of biologic treatment.Results. The results showed 11–13% more patients on MR-pred than on placebo dropped below reimbursement thresholds for the Netherlands, Belgium and the UK. Assuming 1 year of biologics cost €15 000 and MR-pred costs €1/day, €396 are saved in each patient delaying biologic treatment by 12 weeks.Conclusion. Despite a considerably higher cost than conventional prednisone, MR-pred is a cost-effective option for RA patients not on glucocorticoids who are eligible for therapy with biologic agents. [ABSTRACT FROM PUBLISHER]
- Published
- 2013
- Full Text
- View/download PDF
3. The Effect of Low-Dose Glucocorticoids Over Two Years on Weight and Blood Pressure in Rheumatoid Arthritis: Individual Patient Data From Five Randomized Trials.
- Author
-
Palmowski, Andriko, Nielsen, Sabrina M., Boyadzhieva, Zhivana, Hartman, Linda, Oldenkott, Judith, Svensson, Björn, Hafström, Ingiäld, Wassenberg, Siegfried, Choy, Ernest, Kirwan, John, Christensen, Robin, Boers, Maarten, and Buttgereit, Frank
- Subjects
- *
BLOOD pressure , *RHEUMATOID arthritis , *ANTIRHEUMATIC agents , *GLUCOCORTICOIDS , *WEIGHT gain - Abstract
Glucocorticoids reduce disease activity and retard progression of joint damage in rheumatoid arthritis, but current recommendations discourage their use because of drug adverse effects. This study examined the effects of low-dose glucocorticoids on weight gain and hypertension, which are among the more worrisome adverse effects for patients and rheumatologists. Visual Abstract. The Effect of Low-Dose Glucocorticoids Over Two Years on Weight and Blood Pressure in Rheumatoid Arthritis: Individual Patient Data From Five Randomized Trials Glucocorticoids reduce disease activity and retard progression of joint damage in rheumatoid arthritis, but current recommendations discourage their use because of drug adverse effects. This study examined the effects of low-dose glucocorticoids on weight gain and hypertension, which are among the more worrisome adverse effects for patients and rheumatologists. Background: Weight gain and hypertension are well known adverse effects of treatment with high-dose glucocorticoids. Objective: To evaluate the effects of 2 years of low-dose glucocorticoid treatment in rheumatoid arthritis (RA). Design: Pooled analysis of 5 randomized controlled trials with 2-year interventions allowing concomitant treatment with disease-modifying antirheumatic drugs. Setting: 12 countries in Europe. Patients: Early and established RA. Intervention: Glucocorticoids at 7.5 mg or less prednisone equivalent per day. Measurements: Coprimary end points were differences in change from baseline in body weight and mean arterial pressure after 2 years in intention-to-treat analyses. Difference in the change of number of antihypertensive drugs after 2 years was a secondary end point. Subgroup and sensitivity analyses were done to assess the robustness of primary findings. Results: A total of 1112 participants were included (mean age, 61.4 years [SD, 14.5]; 68% women). Both groups gained weight in 2 years, but glucocorticoids led, on average, to 1.1 kg (95% CI, 0.4 to 1.8 kg; P < 0.001) more weight gain than the control treatment. Mean arterial pressure increased by about 2 mm Hg in both groups, with a between-group difference of −0.4 mm Hg (CI, −3.0 to 2.2 mm Hg; P = 0.187). These results were consistent in sensitivity and subgroup analyses. Most patients did not change the number of antihypertensive drugs, and there was no evidence of differences between groups. Limitation: Body composition was not assessed, and generalizability to non-European regions may be limited. Conclusion: This study provides robust evidence that low-dose glucocorticoids, received over 2 years for the treatment of RA, increase weight by about 1 kg but do not increase blood pressure. Primary Funding Source: None. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
4. Barriers and potential solutions in the recruitment and retention of older patients in clinical trials—lessons learned from six large multicentre randomized controlled trials.
- Author
-
Buttgereit, Thomas, Palmowski, Andriko, Forsat, Noah, Boers, Maarten, Witham, Miles D, Rodondi, Nicolas, Moutzouri, Elisavet, Navidad, Antonio Jesus Quesada, Hof, Arnoud W J van't, van der Worp, Bart, Coll-Planas, Laura, Voshaar, Marieke, Wit, Maarten de, Silva, José da, Stegemann, Sven, Bijlsma, Johannes W, Koeller, Marcus, Mooijaart, Simon, Kearney, Patricia M, and Buttgereit, Frank
- Subjects
- *
HUMAN research subjects , *PATIENT participation , *CLINICAL trials , *PATIENT selection , *TIME , *CONFERENCES & conventions , *HEALTH status indicators , *RANDOMIZED controlled trials , *BUSINESS networks , *INTERPROFESSIONAL relations , *HEALTH attitudes , *HEALTH , *INFORMATION resources , *PATIENT-professional relations , *EMOTIONS , *COMORBIDITY , *PERSONNEL management , *COMMUNICATION education , *OLD age - Abstract
Background older people remain underrepresented in clinical trials, and evidence generated in younger populations cannot always be generalized to older patients. Objective to identify key barriers and to discuss solutions to specific issues affecting recruitment and retention of older participants in clinical trials based on experience gained from six current European randomised controlled trials (RCTs) focusing on older people. Methods a multidisciplinary group of experts including representatives of the six RCTs held two networking conferences and compiled lists of potential barriers and solutions. Every item was subsequently allocated points by each study team according to how important it was perceived to be for their RCTs. Results the six RCTs enrolled 7,612 older patients. Key barriers to recruitment were impaired health status, comorbidities and diverse health beliefs including priorities within different cultural systems. All trials had to increase the number of recruitment sites. Other measures felt to be effective included the provision of extra time, communication training for the study staff and a re-design of patient information. Key barriers for retention included the presence of severe comorbidities and the occurrence of adverse events. Long study duration, frequent study visits and difficulties accessing the study site were also mentioned. Solutions felt to be effective included spending more time maintaining close contact with the participants, appropriate measures to show appreciation and reimbursement of travel arrangements. Conclusion recruitment and retention of older patients in trials requires special recognition and a targeted approach. Our results provide scientifically-based practical recommendations for optimizing future studies in this population. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.